Liquidity contract's annual review untrusted to the investment company Bryan, Garnier & Co.

Lyon (France), le 7 janvier 2015 – ERYTECH (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical need, announces today it liquidity contract's annual review untrusted to the investment company Bryan, Garnier & Co.

Under the liquidity contract untrusted to Bryan, Garnier & Co, concerning ERYTECH's shares, the liquidity account held the following assets on 31 December 2014:

- 4 500 ERYTECH's share
- 251 102,67 euros in cash.

It should be noted that during the annual review of 30 June 2014, the following assets have been brought to the liquidity account:

- 3 010 ERYTECH's share
- 289 676,68 euros in cash.

As a reminder, the investment company Bryan, Garnier & Co have signed an amendment to the liquidity contract on march, 25th 2014 in order to proceed to a partial re-absorption of the means allocated to it corresponding to Euros 400 000 on 600 000 Euros initially allocated.

About ERYTECH and ERY-ASP/GRASPA®: www.erytech.com

Founded in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.
Every year about 50,000 patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute leukemia. Today, for about 80% of these patients, mainly adults and relapsing patients, there is no adequate solution due to the toxicity of existing treatments. By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA®, an original and effective treatment that targets leukemia cells through "starvation" while significantly reducing the side effects for patients, and allowing all patients to be treated, even the most fragile ones, representing a market opportunity of more than EUR 1 billion. GRASPA® is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product received FDA clearance to start clinical development in ALL in the USA. ERYTECH has concluded distribution partnership agreements for Europe with Orphan Europe (Recordati Group), and with TEVA for Israel.
The company is also developing other indications in solid tumors and certain orphan indications outside oncology. ERYTECH has its own GMP-approved and operational manufacturing site.

ERYTECH is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharm. & Bio and Next Biotech indexes.

Contacts

ERYTECH

Gil Beyen
Chairman and CEO

Pierre-Olivier Goineau
Vice President and COO

Tél : 04 78 74 44 38
investors@erytech.com

*New***Cap.**

Investor and press relations
Julien Perez / Emmanuel Huynh
Tél : 01 44 71 98 52
erytech@newcap.fr